Recombinant lactic acid bacteria as mucosal biotherapeutic agents

C. Daniel, Y. Roussel, M. Kleerebezem, B. Pot

Research output: Contribution to journalArticleAcademicpeer-review

57 Citations (Scopus)


The safety status of lactic acid bacteria (LAB) and their capacity to survive the passage through the gastrointestinal tract (GI tract) have rendered them excellent candidates for the production of therapeutic proteins and their delivery in situ to the GI tract. During the past two decades, major health benefits of mucosally administered recombinant LAB have been successfully demonstrated, predominantly using animal models. However, the field has recently moved into the era of human clinical trials. In this review, we provide a timely update on the recent important advances made in this field, and outline the potential of recombinant LAB as therapeutic tools for their safe and efficient use in human health.
Original languageEnglish
Pages (from-to)499-508
JournalTrends in Biotechnology
Issue number10
Publication statusPublished - 2011


  • lactobacillus-plantarum genes
  • modified lactococcus-lactis
  • in-vivo
  • immunomodulatory properties
  • listeria-monocytogenes
  • protective antigen
  • immune-responses
  • epithelial-cells
  • vaccine delivery
  • lethal challenge

Fingerprint Dive into the research topics of 'Recombinant lactic acid bacteria as mucosal biotherapeutic agents'. Together they form a unique fingerprint.

Cite this